Moreover, contrary to the CML setting where attempts for international MRD standardization are ongoing since the middle of the 2000′s, consensus guidelines for the assessment of the e1a2 BCR-ABL transcript in Ph+ ALL have been established only recently by the EuroMRD Consortium [5]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.